Trial Profile
A Randomized, Placebo-Controlled, Subject- and Investigator-Blind, Single and Multiple Dose, Safety, Tolerability, and Pharmacokinetics Study of LY3463251 in Healthy and Overweight Healthy Subjects
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 23 Dec 2020
Price :
$35
*
At a glance
- Drugs LY 3463251 (Primary)
- Indications Unspecified
- Focus Adverse reactions
- Sponsors Eli Lilly and Company
- 18 Dec 2020 Status changed from recruiting to discontinued due to an insufficient benefit/tolerability ratio.
- 16 Jun 2020 Planned End Date changed from 20 Dec 2020 to 10 Apr 2021.
- 16 Jun 2020 Planned primary completion date changed from 20 Dec 2020 to 10 Apr 2021.